Literature DB >> 28630196

Antimicrobial Susceptibility Trends among Staphylococcus aureus Isolates from U.S. Hospitals: Results from 7 Years of the Ceftaroline (AWARE) Surveillance Program, 2010 to 2016.

Helio S Sader1, Rodrigo E Mendes2, Jennifer M Streit2, Robert K Flamm2.   

Abstract

We evaluated trends in Staphylococcus aureus antimicrobial susceptibility in U.S. hospitals in the 2010-2016 period. A total of 21,056 clinical isolates from 42 medical centers were tested for susceptibility by broth microdilution methods. Methicillin-resistant S. aureus (MRSA) rates decreased from 50.0% (in 2010) to 42.2% (in 2016). Susceptibility to erythromycin, levofloxacin, and clindamycin increased slightly, whereas susceptibility to ceftaroline, trimethoprim-sulfamethoxazole, and tetracycline remained stable. Ceftaroline retained potent activity against methicillin-susceptible S. aureus (MSSA) and MRSA (97.2% susceptible) with no marked variations.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  MRSA; ceftaroline; cephalosporin; methicillin-resistant Staphylococcus aureus; skin and skin structure infection

Mesh：

Substances：

Year:  2017        PMID： 28630196      PMCID： PMC5571371          DOI： 10.1128/AAC.01043-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

Review 1.  Antimicrobial resistance: Not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician's guide to community MRSA - its evolving antimicrobial resistance and implications for therapy.

Authors:  Kyra Chua; Frederic Laurent; Geoffrey Coombs; M Lindsay Grayson; Benjamin P Howden
Journal:  Clin Infect Dis       Date:  2011-01-01       Impact factor: 9.079

Review 2.  Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.

Authors:  James E Frampton
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

3.  Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk.

Authors:  B C Herold; L C Immergluck; M C Maranan; D S Lauderdale; R E Gaskin; S Boyle-Vavra; C D Leitch; R S Daum
Journal:  JAMA       Date:  1998-02-25       Impact factor: 56.272

4.  Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013.

Authors:  Helio S Sader; David J Farrell; Rodrigo E Mendes; Robert K Flamm; Mariana Castanheira; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2015-02-10       Impact factor: 2.803

Review 5.  Life After USA300: The Rise and Fall of a Superbug.

Authors:  Paul J Planet
Journal:  J Infect Dis       Date:  2017-02-15       Impact factor: 5.226

6.  Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014.

Authors:  Lindsey M Weiner; Amy K Webb; Brandi Limbago; Margaret A Dudeck; Jean Patel; Alexander J Kallen; Jonathan R Edwards; Dawn M Sievert
Journal:  Infect Control Hosp Epidemiol       Date:  2016-08-30       Impact factor: 3.254

7.  Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men.

Authors:  Binh An Diep; Henry F Chambers; Christopher J Graber; John D Szumowski; Loren G Miller; Linda L Han; Jason H Chen; Felice Lin; Jessica Lin; Tiffany HaiVan Phan; Heather A Carleton; Linda K McDougal; Fred C Tenover; Daniel E Cohen; Kenneth H Mayer; George F Sensabaugh; Françoise Perdreau-Remington
Journal:  Ann Intern Med       Date:  2008-01-30       Impact factor: 25.391

8.  Characterization of baseline methicillin-resistant Staphylococcus aureus isolates recovered from phase IV clinical trial for linezolid.

Authors:  Rodrigo E Mendes; Helio S Sader; Lalitagauri M Deshpande; Binh An Diep; Henry F Chambers; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2009-11-25       Impact factor: 5.948

Review 9.  Waves of resistance: Staphylococcus aureus in the antibiotic era.

Authors:  Henry F Chambers; Frank R Deleo
Journal:  Nat Rev Microbiol       Date:  2009-09       Impact factor: 60.633

10.  Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011-2012).

Authors:  Helio S Sader; Rodrigo E Mendes; David J Farrell; Robert K Flamm; Ronald N Jones
Journal:  Pediatr Infect Dis J       Date:  2014-08       Impact factor: 2.129
View more
  14 in total

1.  Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers.

Authors:  Helio S Sader; Rodrigo E Mendes; Leonard R Duncan; Michael A Pfaller; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

2.  Staphylococcus aureus Resistance Patterns in Wisconsin: 2018 Surveillance of Wisconsin Organisms for Trends in Antimicrobial Resistance and Epidemiology (SWOTARE) Program Report.

Authors:  Rebecca H Schulte; Erik Munson
Journal:  Clin Med Res       Date:  2019-10-03

3.  Comparative In Vitro Activities of Ceftaroline and Tedizolid against Clinical Strains of Staphylococcus aureus and Enterococcus: Results from the China Antimicrobial Surveillance Network (CHINET) in 2018.

Authors:  Yan Guo; Yang Yang; Yonggui Zheng; Shi Wu; Dandan Yin; Demei Zhu; Fupin Hu
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

4.  Antibiotic Resistance Rates by Geographic Region Among Ocular Pathogens Collected During the ARMOR Surveillance Study.

Authors:  Penny A Asbell; Rahul T Pandit; Christine M Sanfilippo
Journal:  Ophthalmol Ther       Date:  2018-08-09

5.  Antibiotic resistance among ocular pathogens: current trends from the ARMOR surveillance study (2009-2016).

Authors:  Randall K Thomas; Ron Melton; Penny A Asbell
Journal:  Clin Optom (Auckl)       Date:  2019-03-12

6.  The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program.

Authors:  Daniel J Diekema; Po-Ren Hsueh; Rodrigo E Mendes; Michael A Pfaller; Kenneth V Rolston; Helio S Sader; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

7.  Twenty-Year Trends in Antimicrobial Susceptibilities Among Staphylococcus aureus From the SENTRY Antimicrobial Surveillance Program.

Authors:  Daniel J Diekema; Michael A Pfaller; Dee Shortridge; Marcus Zervos; Ronald N Jones
Journal:  Open Forum Infect Dis       Date:  2019-03-15       Impact factor: 3.835

8.  Trends in Antibiotic Resistance Among Ocular Microorganisms in the United States From 2009 to 2018.

Authors:  Penny A Asbell; Christine M Sanfilippo; Daniel F Sahm; Heleen H DeCory
Journal:  JAMA Ophthalmol       Date:  2020-05-01       Impact factor: 7.389

9.  The use of extrapolation based on modeling and simulation to support high-dose regimens of ceftaroline fosamil in pediatric patients with complicated skin and soft-tissue infections.

Authors:  Phylinda L S Chan; Lynn McFadyen; Andrea Quaye; Heidi Leister-Tebbe; Victoria M Hendrick; Jennifer Hammond; Susan Raber
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-05-01

10.  Genomic Update of Phenotypic Prediction Rule for Methicillin-Resistant Staphylococcus aureus (MRSA) USA300 Discloses Jail Transmission Networks with Increased Resistance.

Authors:  Sarah E Sansom; Emily Benedict; Stephanie N Thiede; Bala Hota; Alla Aroutcheva; Darjai Payne; Chad Zawitz; Evan S Snitkin; Stefan J Green; Robert A Weinstein; Kyle J Popovich
Journal:  Microbiol Spectr       Date:  2021-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.